A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Condyloma Acuminatum in Patients With HIV Infection
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 11
研究概览
简要总结
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection. To investigate whether topical HPMPC therapy can induce regression of condyloma acuminatum in patients with HIV infection.
详细描述
Four groups of 10 patients each receive topical HPMPC at 0.3 percent concentration for 5 or 10 days total or 1.0 percent concentration for 5 or 10 days total, followed by 2 weeks of rest. When six patients at a given dose and schedule have completed treatment and follow-up without significant toxicity, subsequent patients are entered at the next higher dose level. Patients are evaluated twice weekly during treatment and once weekly during the rest period. HPMPC may be extended for up to two additional courses in patients who experience no significant toxicity.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •AZT, ddI, ddC, d4T, or 3TC.
- •Oral trimethoprim/sulfamethoxazole.
- •Aerosolized pentamidine.
- •Fluconazole.
- •Rifabutin.
- •Clarithromycin.
- •Patients must have:
- •HIV seropositivity.
- •Mean CD4 count >= 100 cells/mm
- •External anogenital condyloma acuminatum confirmed by biopsy, present for less than 1 year. NOTE:
- •Warts on anal, urethral, or vaginal mucosa will not be studied.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Active lesions of genital herpes, other skin wounds, or active inflammatory skin disorders in the same area as warts to be treated.
- •Active medical problems sufficient to hinder study compliance.
- •Concurrent Medication:
- •Podofilox or any podophyllum resin preparation.
- •Liquid nitrogen treatment.
- •Interferon alpha.
- •Trichloracetic acid.
- •Other treatments, topical or systemic, surgical or ablative, known to have anti-papilloma activity.
- •Other investigative drugs (except d4T or 3TC) unless approved by the sponsor.
- •Patients with the following prior conditions are excluded:
- •History of untreated syphilis or Bowenoid papulosis.
- •Prior Medication:
- •Excluded within 4 weeks prior to study entry:
- •Treatment for anogenital warts.
- •Immunomodulators (including interferons or systemic corticosteroids).
- •Lymphocyte replacement therapy.
- •Biologic response modifiers. Substance abuse.